A source close to the matter told Reuters there is "no deal" and there "never was a deal to be done" between the two drugmakers ...

AstraZeneca shares were slumping while Bristol-Myers Squibb’s stock was jumping on Monday on reported deal talks. But the big question is why these two pharmaceutical giants would want to come ...

Shares of Bristol Myers Squibb ( BMY) were up over 4% in premarket trading to their highest point since early 2023 following a report that the company held merger talks with AstraZeneca ( AZN ), ...

Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Investors reacted negatively to ...

Asad Haider, Goldman Sachs Healthcare Analyst, joins 'Closing Bell Overtime' to talk a possible merger between Bristol Myers and AstraZeneca.

AstraZeneca declined to comment, while Bristol Myers Squibb did not immediately respond to CNBC's request for comment outside ...

Rumors of an AstraZeneca PLC-Bristol-Myers Squibb Company merger are cooling. Click here for risks and drug portfolio ...

British drugmaker AstraZeneca Plc and US-based Bristol Myers Squibb have held preliminary discussions about a possible merger that could create one of the world's largest pharmaceutical companies with ...

According to a Reuters report, a senior source denied merger discussions between AstraZeneca and Bristol Myers Squibb.

AstraZeneca is considering a merger with Bristol Myers Squibb, potentially valued at $400 billion. Talks have occurred for several months, but no formal agreement is expected soon. AstraZeneca shares ...

AstraZeneca (LSE:AZN) is reported to be in advanced merger talks with Bristol Myers Squibb. The potential deal could create a combined pharmaceutical company valued at about US$400b. The transaction, ...

A combination of the two pharmaceutical companies could create an entity valued at nearly $400 billion, according to the Financial Times ...